Itovyom OD Capsule contains Itopride 150 mg as the active ingredient, a prokinetic agent indicated for the treatment of gastrointestinal motility disorders. Itopride acts by enhancing acetylcholine release through dopamine D2 receptor antagonism and inhibiting acetylcholinesterase activity, thereby promoting gastric emptying and improving gastrointestinal motility. Itovyom OD Capsule is primarily prescribed for conditions such as functional dyspepsia, gastroparesis, and other disorders characterized by delayed gastric emptying and impaired gastrointestinal motility. The once-daily formulation ensures sustained therapeutic plasma levels, improving patient compliance. Clinical studies have demonstrated its efficacy in reducing symptoms including bloating, nausea, vomiting, early satiety, and abdominal discomfort associated with motility dysfunction. Itovyom OD Capsule is generally well tolerated; common adverse effects may include mild diarrhea, abdominal cramps, and dizziness. It should be used with caution in patients with gastrointestinal bleeding, obstruction, or perforation. Contraindications include hypersensitivity to Itopride or any excipients. It is advisable to consult a healthcare professional before initiating therapy, especially in patients with hepatic or renal impairment. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential side effects.